LTEN Excellence Awards Unboxed Wins Prestigious LTEN Excellence Award for Learning Content
RICHMOND, Va., September 21, 2023 (Newswire.com)
-
Unboxed Training & Technology, a leading provider of innovative training solutions, is thrilled to announce its prestigious recognition as the recipient of the LTEN Excellence Award for Learning Content. The award was presented at the 9th Annual LTEN Excellence Awards ceremony, held during the 52nd LTEN Annual Conference in Phoenix, Arizona.
The LTEN Excellence Award for Learning Content recognizes Unboxed's remarkable impact on employee training in the Life Sciences & Pharma Industry. Unboxed's expertise and innovative approach enabled the development of training programs that delivered exceptional results, empowering global sales professionals to excel in their roles.
"We are incredibly honored to receive this award in collaboration with our global Pharma clients. The field of finalists in the category were among the best in the industry, and I'm very proud of our team for showcasing our commitment to Excellence through their work." - Unboxed's President, Dave Romero
About LTEN: LTEN, the Life Sciences Trainers & Educators Network, is the foremost professional awards program that acknowledges excellence, innovation, and performance in life sciences training. A panel of esteemed judges evaluated nominees in various categories, making this achievement a testament to Unboxed Training & Technology's outstanding contributions to the industry.
Lauren Harbert, Executive Director of LTEN, commented, "It was a true honor to recognize the talent involved in this year's awards program. We had by far the most nominees ever this year, and each one of those nominees was deserving of an award. This was without question an extremely challenging year for our judges. Their hard work paid off though; the quality of this year's award winners is nothing short of incredible."
About Unboxed: Unboxed's commitment to delivering cutting-edge training solutions and achieving excellence has solidified its position as a leader in the industry. The LTEN Excellence Award for Learning Content serves as a testament to the company's dedication to providing exceptional learning experiences that drive impactful results.
Unboxed is a leading provider of innovative training solutions with a focus on delivering engaging and impactful learning experiences. Unboxed combines technology, creativity, and strategy to develop customized training programs. Unboxed enables organizations to drive performance, improve employee productivity, and achieve their business objectives. For more information, visit www.unboxedtechnology.com.
For more information on the LTEN Excellence Awards and a list of past winners, please visit https://www.l-ten.org/awards/
As published in Frontiers in Pharmacology, the biopharmaceutical drug development firm's sponsored research has identified and validated cannabinoid ratio-controlled, Minimum Essential Mixtures (MEM) for the treatment of Parkinson's disease symptoms
Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, has co-published a study in the journal Frontiers in Pharmacologythat demonstrates the efficacy of its proprietary cannabinoid-containing, minimum essential mixtures (MEM) for the treatment of Parkinson's disease (PD). There is a great clinical need for improved therapeutics, and the market for Parkinson's disease treatments is expected to grow to $8.8 billion by 2026.
"Our drug discovery process has identified promising ratio-controlled mixtures of cannabis-inspired compounds for the treatment of Parkinson's disease, which have proven effective at reducing Parkinsonian motor symptoms in an animal model of the disease," said Dr. Andrea Small Howard, President, Chief Science Officer, and Director of Gb Sciences. "This study allows us to continue addressing unmet clinical needs through the development of novel plant-inspired drugs, and positions Gb Sciences as a contributor to the expanding world of novel PD therapeutics."
For this Gb Sciences-sponsored study, the discovery research using cell models of Parkinson's disease was performed at Chaminade University (Honolulu, Hawai'i, USA), and the MEM refinement and validation research was performed in a zebrafish model of Parkinson's disease at the National Research Council of Canada (NRC). The study entitled "Identification of minimum essential therapeutic mixtures from Cannabis plant extracts by screening in cell and animal models of Parkinson's disease" was co-authored by Gb Sciences' own President and Chief Science Officer Andrea Small-Howard and her collaborators Michael G. Morash, Jessica Nixon, and Lee Ellis from the National Research Council of Canada; Lori M.N. Shimoda and Helen Turner from Chaminade University of Honolulu; and Alexander J. Stokes from the University of Hawai'i at Manoa (Manoa, Hawai'i, USA).
The sequentially reductionist process implemented in this multi-site study preserves some of the entourage-like effects of whole plant extracts while achieving "relative" simplicity within MEM that is a requirement for obtaining the manufacturing and quality control advantages of single-ingredient drugs. This paper identifies promising minimal essential mixtures of cannabinoids based on a step-wise, strategic approach to reducing the complexity of the plant secondary metabolome. The sequential use of insilico, in vitro, and medium throughput in vivo experimental systems has generated refined, de-risked mixtures that can now be tested in additional, higher-cost, preclinical model systems of PD.
Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary GbS Global Biopharma, Inc. The "plant-inspired" active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences' intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences' lead program for Parkinson's disease is being prepared for a first-in-human clinical trial. Gb Sciences' formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada. The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
